Navigation Links
Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
Date:12/21/2012

San Diego, CA (PRWEB) December 21, 2012

Stemedica Cell Technologies, Inc., a leading manufacturer of adult ischemia tolerant allogeneic stem cells and stem cell factors announced that the Company has signed an agreement with The Scripps Research Institute to investigate the role of Stemedica’s ischemia tolerant human mesenchymal stem cells and stem cell factors as a therapy for severe lung injury and sepsis.

Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are the most common causes of respiratory failure among critically ill patients. The mortality for this syndrome remains high at 30-40% and accounts for approximately 75,000 deaths per year. Severe bacterial pneumonia is the most common cause of ALI/ARDS and is frequently associated with septic shock. The only intervention for ALI/ARDS that has resulted in a mortality benefit is low tidal volume ventilation. Despite several attempts, there have been no pharmacological agents that have reduced the morbidity or mortality from ALI/ARDS. Furthermore, treatment of bacterial pneumonia is increasingly hampered by the rapid spread of multi-drug resistant bacteria and the lack of new antimicrobial agents to treat them. Therefore, given the large public health impact of severe bacterial pneumonia and ALI/ARDS, novel therapies are needed to address this common and growing clinical problem.

Bone marrow derived mesenchymal stem cells (MSCs) are an emerging form of cell-based therapy that have been increasingly studied in experimental models of lung injury and sepsis. Experimental studies have shown that murine MSCs can improve survival, reduce lung injury, and enhance bacterial clearance in clinically relevant models of bacterial pneumonia in mice. These beneficial effects have also been achieved using human MSCs in an ex-vivo human lung model of ALI.

Naveen Gupta, MD, Assistant Professor of Molecular and Experimental Medicine and Principal Investigator at The Scripps Research Institute, has authored and co-authored a number of publications in peer-reviewed journals in this field. He commented that, “This project will investigate the therapeutic effects of Stemedica’s ischemia tolerant MSCs in experimental lung injury and sepsis. Specifically, it will determine the optimal route, dose and timing of cell delivery in an E. coli pneumonia model. In addition, studies will be done using purified soluble factors secreted by the stem cells to determine whether a therapeutic effect comparable to using live MSCs can be achieved.” Dr. Gupta continued: “Given Stemedica's expertise in the field of developing MSC-based clinical therapies and the scientific and clinical expertise in Pulmonary and Critical Care Medicine present at Scripps, I believe that this will be a mutually beneficial and productive collaboration that may have important implications in how cell based therapy is applied to critically ill patients.”

Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica noted, “One of the great advantages of using Stemedica’s cGMP produced, FDB licensed (Food & Drug Branch of the California Department of Public Health) stem cells is that they have already been approved by the Food and Drug Administration for use in a variety of clinical trials. The same cGMP manufactured cell can be used in all phases of the approval process from preclinical through clinical trials and ultimately to commercialization. This will contribute significantly to accelerating the process from benchtop to bedside.”

Maynard Howe, Ph.D., Vice Chairman and Chief Executive Officer of Stemedica commented, “We are pleased to be working with a renowned organization like Scripps to advance treatment for this critical condition. The goals of our organizations are aligned--we strive to save lives--and one of the most meaningful ways we can do this is to stem mortality from ARDS.”

About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, TSRI has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists (including three Nobel laureates) work toward their next discoveries. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see http://www.scripps.edu.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke, acute myocardial infarction, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

For more information please contact Dave McGuigan at dmcguigan (at) Stemedica(dot)com

Read the full story at http://www.prweb.com/releases/stemedica-scripps-ards/stem-cell-factors-sepsis/prweb10263983.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scripps Florida scientists create new approach to destroy disease-associated RNAs in cells
2. Scripps Florida scientists develop new compound that reverses fatty liver disease
3. Scripps Florida scientist awarded $2.5 million to study inner workings of memory formation
4. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
5. Scripps Research Institute study points to potential new therapies for cancer and other diseases
6. 2 Scripps Research Institute scientists honored by American Chemical Society
7. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
8. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
9. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
10. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
11. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: